Biote (BTMD) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BTMD Biote Corp BTMD
70 GF Score
Price $2.47
GF Value $3.07
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Biote Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Biote is: High Risk: High uncertainty with risk-return tradeoff.

Biote  (NAS:BTMD) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Biote Risk Assessment Related Terms

BTMD vs DCGO, PIII, EHSI: Risk Assessment Comparison

For the Medical Care Facilities subindustry, Biote's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biote Risk Assessment vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Biote's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Biote's Risk Assessment falls into.


BTMD
70GF Score
Biote Corp BTMD
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biote (BTMD) Overvalued in 2026?

Based on GuruFocus' analysis, Biote stock appears to be undervalued. The current stock price of $2.47 is trading 19.5% below its estimated GF Value™ of $3.07. GuruFocus considers Biote to be Modestly Undervalued.

Key valuation signals for BTMD:

  • Risk Assessment:
  • GF Value™: $3.07 vs. price of $2.47 (19.5% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the BTMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biote Business Description

Address 1875 W. Walnut Hill Lane, Suite 100, Irving, TX, USA, 75038
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
70GF Score

Get the complete analysis for BTMD

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.47
Price
$3.07
GF Value